From March 15 to 18, 2024, the 21st China Association of Clinical Laboratory Practice Expo (CACLP) and the 4th China International IVD Upstream Raw Materials Manufacturing & Supply Chain Expo (CISCE) were held at the Chongqing International Expo Center.
The exhibition brought together more than 1,300 IVD companies from over 19 countries and regions, covering the entire in vitro diagnostics industry chain, from upstream to downstream. At the event, Medconn showcased its latest HbA1c testing solutions and technological advancements, attracting a steady stream of visitors to its booth.
Event Highlights
DX-9000 Fully Automated HbA1c & Hematology Line
MQ-8000 Triple-Analyzer System
Medconn's booth attracted considerable attention, with its striking DX-9000 Fully Automated HbA1c & Hematology Line and self-developed MQ-8000 Triple-Analyzer System drawing large numbers of visitors for consultations and technical exchanges.
At the exhibition, Medconn presented these two integrated automation solutions as part of its vision for total laboratory automation. Designed to optimize clinical laboratory management and workflow efficiency, the solutions can help improve productivity, reduce error rates, minimize blood sample requirements, shorten turnaround times, reduce reliance on STAT testing, and enhance laboratory biosafety—providing laboratories with a more efficient and reliable solution.
Distributor Conference
Another highlight of the exhibition was the Medconn & Jingjiang HbA1c and Hematology Automation Solutions Distributor Conference, hosted by Medconn under the theme “Quality Builds the Brand, Expertise Creates a Win-Win Future.”
The theme reflected the shared mission and commitment of Medconn and Jingjiang Diagnostics. By combining Medconn's expertise and leadership in HbA1c testing with Jingjiang's strong R&D capabilities, the two companies joined forces to develop an HbA1c and hematology automation line featuring multiple advantages and flexible configurations.
Multiple Modes, Flexible Solutions
The system offers multiple operating modes designed to address different laboratory needs:
Customization Mode
- Set testing priorities according to individual laboratory preferences.
Expansion Mode
- Provides enhanced testing capabilities to support the assessment and management of vascular complications in patients with diabetes.
Speed Mode
- During periods of high sample volumes, samples are prioritized and routed to the high-speed module.
Economy Mode
- Samples are preferentially routed to lower-cost testing modules to help optimize laboratory resources.
The satellite symposium attracted a large audience of industry professionals. During the session, Dr. Chujianjun, Founder of Jingjiang Diagnostics, introduced the company's distinctive product features, sparking an active Q&A session among attendees.
Medconn's Marketing Department also provided an in-depth presentation on the clinical value of combined HbA1c and complete blood count (CBC) testing, highlighting the importance of integrated testing and presenting hematology solutions designed to meet the needs of clinical laboratories.
The session generated strong interest, with many attendees continuing discussions and consultations after the event.
United by Purpose, Striving for Excellence
Looking ahead, Medconn will continue to uphold a customer-centric approach, driving continuous innovation in both technology and service. By consistently improving the quality of its products and services, Medconn is committed to supporting the continued growth and advancement of China's in vitro diagnostics industry.
